BioCentury
ARTICLE | Emerging Company Profile

ImmusanT: Having their cake

ImmusanT's vaccine could allow celiac patients to eat normally

March 26, 2012 7:00 AM UTC

ImmusanT Inc. is developing what could be the first treatment for celiac disease that allows patients to eat a normal diet. The company's Nexvax2 vaccine seeks to reprogram CD4+ T cells to induce gluten tolerance.

The biotech also is developing a blood-based companion diagnostic. Both programs were acquired from Nexpep Pty. Ltd., which is now a shell company...